Ionis and Biogen have secured FDA approval for their spinal muscular atrophy drug, working closely with the FDA and tapping into a trifecta of incentives -- including fast-track designation, priority review and orphan drug designation.
Biogen and Ionis Pharmaceuticals could soon deliver the first-ever treatment for spinal muscular atrophy. Meanwhile, carrier screening that could prevent the disorder goes unfunded.
Meevo offers an all-in-one solution for managing salon and spa employees. From scheduling and time tracking to payroll and promotions, Meevo streamlines operations and supports growth.